Decision curve analysis
Menée sur 1 003 patients ayant subi une biopsie de la prostate entre 2007 et 2014, cette étude évalue, par rapport à une biopsie écho-guidée standard, la performance d'une biopsie ciblée à l'aide de fusions d'images échographiques et d'IRM pour diagnostiquer un cancer de la prostate
Decision curve analysis (DCA) is a method for evaluating the benefits of a diagnostic test across a range of patient preferences for accepting risk of undertreatment and overtreatment to facilitate decisions about test selection and use.1 In this issue of JAMA, Siddiqui and colleagues2 used DCA to evaluate 3 prostate biopsy strategies: targeted magnetic resonance/ultrasound fusion biopsy, standard extended-sextant biopsy, or a combination, for establishing the diagnosis of intermediate- to high-risk prostate cancer. Their goal was to identify the best biopsy strategy to ensure prostatectomy is offered to patients with intermediate- and high-risk tumors and avoided for patients with low-risk tumors.
JAMA , commentaire, 2014